Literature DB >> 25924820

Signal detection in FDA AERS database using Dirichlet process.

Na Hu1, Lan Huang2, Ram C Tiwari2.   

Abstract

In the recent two decades, data mining methods for signal detection have been developed for drug safety surveillance, using large post-market safety data. Several of these methods assume that the number of reports for each drug-adverse event combination is a Poisson random variable with mean proportional to the unknown reporting rate of the drug-adverse event pair. Here, a Bayesian method based on the Poisson-Dirichlet process (DP) model is proposed for signal detection from large databases, such as the Food and Drug Administration's Adverse Event Reporting System (AERS) database. Instead of using a parametric distribution as a common prior for the reporting rates, as is the case with existing Bayesian or empirical Bayesian methods, a nonparametric prior, namely, the DP, is used. The precision parameter and the baseline distribution of the DP, which characterize the process, are modeled hierarchically. The performance of the Poisson-DP model is compared with some other models, through an intensive simulation study using a Bayesian model selection and frequentist performance characteristics such as type-I error, false discovery rate, sensitivity, and power. For illustration, the proposed model and its extension to address a large amount of zero counts are used to analyze statin drugs for signals using the 2006-2011 AERS data.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  false discovery rate; information component; pseudo-Bayes factor; pseudo-maximum likelihood; reporting rates; zero-inflated Poisson model

Mesh:

Year:  2015        PMID: 25924820     DOI: 10.1002/sim.6510

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.

Authors:  Keith B Hoffman; Mo Dimbil; Nicholas P Tatonetti; Robert F Kyle
Journal:  Drug Saf       Date:  2016-06       Impact factor: 5.606

2.  Mixture drug-count response model for the high-dimensional drug combinatory effect on myopathy.

Authors:  Xueying Wang; Pengyue Zhang; Chien-Wei Chiang; Hengyi Wu; Li Shen; Xia Ning; Donglin Zeng; Lei Wang; Sara K Quinney; Weixing Feng; Lang Li
Journal:  Stat Med       Date:  2017-11-23       Impact factor: 2.373

3.  Efficient methods for signal detection from correlated adverse events in clinical trials.

Authors:  Guoqing Diao; Guanghan F Liu; Donglin Zeng; William Wang; Xianming Tan; Joseph F Heyse; Joseph G Ibrahim
Journal:  Biometrics       Date:  2019-03-29       Impact factor: 2.571

4.  A tree-based scan statistic for zero-inflated count data in post-market drug safety surveillance.

Authors:  Goeun Park; Inkyung Jung
Journal:  Sci Rep       Date:  2022-09-29       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.